

## IAMA France has chosen MI-mAbs as one key partner for the development of its innovative immunotherapy antibodies

IAMA France will take full advantage of MI-mAbs' integrated innovation platform for the development of therapeutic antibody candidates in the fields of infectious diseases and cancer.

**MARSEILLE, France - December 9, 2019** – MI-mAbs, the French demonstrator of immunotherapy antibodies, today announced that it has signed an agreement with IAMA France, a Paris-based biotechnology company, to develop antibodies, within their immunotherapy program, targeted against infectious diseases and cancers.

Following on an initial fruitful collaboration with MI-mAbs, IAMA France has now entrusted the platform with the task of generating part of the antibodies within their immunotherapy programs. IAMA has already consulted MI-mAbs for scientific advice towards completion of a strategic development plan that should optimize their antibody R&D process. In the framework of the agreement announced today, MI-mAbs will generate antibodies in recombinant formats, produce and select the best candidates among them, deploying its full expertise in early antibody development.

*“We look forward to this exciting collaboration with IAMA France”, said **François Romagné, Scientific Director of MI-mAbs**. “It is a good example of the kind of projects that we had in mind when building MI-mAbs, projects that use our platform as a remote laboratory, and our expertise and know-how to navigate the different steps of early-stage antibody development. We hope to work hand-in-hand with IAMA France in this exciting project”.*

*“MI-mAbs' platform gathers a tremendous amount of knowledge in the development of therapeutic antibodies, we were very impressed with our first experience working with them”, said **Samuel Salot, in charge of R&D operations for IAMA France**. “We particularly appreciated the team's professionalism, knowledge in immunotechnologies and transparency, key elements for companies like ours that externalize part of their R&D processes. We look forward to starting the generation of our immunotherapy antibodies”.*

Financial details on the agreement are not disclosed.

## About MI-mAbs

MI-mAbs is the French demonstrator of immunotherapy antibodies. By converting the most promising targets from academia, startups and industry into drug candidates and developing cutting-edge immunotechnologies, MI-mAbs allows research institutions, public technology transfer offices and biotech companies to de-risk the development of next generation immunotherapies against cancer, inflammation and other diseases. Located in the historical birthplace of Marseille Immunopôle, MI-mAbs homes a fully integrated suite of platforms covering all steps leading to preclinical proof-of-concept.

Prize-Winner of the program "Investments for the Future" in the "pre-industrial demonstrators" category, MI-mAbs was founded in 2011 by Aix-Marseille University (AMU) and its subsidiary Protisvalor, the CNRS, the Inserm, the Institut Paoli-Calmettes (IPC), the French leader in Immuno-Oncology, Innate Pharma and one of the world's leaders in healthcare, Sanofi; AMU and Protisvalor ensure its administration. MI-mAbs is a founding member of the French immunology cluster Marseille Immunopôle.

For more information please visit [www.mimabs.org](http://www.mimabs.org).

## Contact

### ATCG-Press

**Marie PUVIEUX (France)**

+33 (0)6 10 54 36 72

**Ana Maria Leon Ortiz (ROW)**

+33 (0)7 71 82 12 29

[mimabs@atcg-partners.com](mailto:mimabs@atcg-partners.com)